TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10649262

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 59994

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59994
Study: 9312206

Group type: EXPERIMENTAL
Intervention: Intrapulmonary SCT (delivered via dry powder inhaler)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular SCT (IM)
Number of subjects: 0
Study: 7865076

Group type: EXPERIMENTAL
Intervention: NaF dentifrices (1000 or 1500 micrograms F/g)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Na2FPO3 dentifrices (1000 or 1500 micrograms F/g)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: NaF dentifrices
Number of subjects: 474

Group type: COMPARATOR
Intervention: Na2FPO3 dentifrices
Number of subjects: 474
Study: 2511277

Group type: EXPERIMENTAL
Intervention: 100 micrograms of recombinant IFN-gamma given once weekly
Number of subjects: 22

Group type: COMPARATOR
Intervention: Patients with refractory disease
Number of subjects: 22
Study: 240112

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Beta adrenergic blocking agents
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Combination of beta adrenergic blocking agents with peripheral vasodilators (e.g., hydrallazine, prazosin)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Hydrallazine
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Thiazide diuretics
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 591
Study: 31601424

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 124
Study: 31513552

Group type: EXPERIMENTAL
Intervention: Community empowerment model of combination HIV prevention (Project Shikamana)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 496
Study: 28025462

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 1517

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 1517

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1517

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 1517
Study: 23153843

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 7812

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 7812

Group type: EXPERIMENTAL
Intervention: CABG and PCI
Number of subjects: 7812
Study: 20079922

Group type: EXPERIMENTAL
Intervention: 0.59-mg FA intravitreal implant
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard of care (SOC) with systemic prednisolone or equivalent corticosteroid
Number of subjects: 140
Study: 18956517

Group type: EXPERIMENTAL
Intervention: Involved-node (IN) radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard involved-field (IF) radiotherapy
Number of subjects: 0
Study: 15983798

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clonidine 0.2 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg + Clonidine 0.2 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11921330

Group type: EXPERIMENTAL
Intervention: Ovarian cancer survivors
Number of subjects: 49
Study: 10659924

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (estradiol 50 microg/day) combined with oral medroxyprogesterone acetate (MPA) 10 mg/day for 12 days/month
Number of subjects: 38

Group type: COMPARATOR
Intervention: Tibolone tablets 2.5 mg/day
Number of subjects: 38
Study: 7626294

Group type: EXPERIMENTAL
Intervention: Ponsky‐Gauderer type
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sachs‐Vine gastrostomy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 44
Study: 2695475

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (various types)
Number of subjects: 14
Study: 835502

Group type: EXPERIMENTAL
Intervention: High fat diet (70% fat, 20% protein, 10% carbohydrate)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (70% carbohydrate, 20% protein, 10% fat)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High fat diet
Number of subjects: 10
Study: 31393444

Group type: EXPERIMENTAL
Intervention: Intramuscular Retinalamin injections
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study: 27207089

Group type: EXPERIMENTAL
Intervention: Causal beliefs regarding depression
Number of subjects: 77
Study: 26105520

Group type: EXPERIMENTAL
Intervention: Pomegranate extract (PE) 900 mg daily before surgery
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no PE intake)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pomegranate extract (PE)
Number of subjects: 35
Study: 23182608

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 μg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.50 μg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.75 μg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 μg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Remifentanil 1.25 μg/kg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 75
Study: 21653300

Group type: EXPERIMENTAL
Intervention: Intervention group physicians
Number of subjects: 88000

Group type: COMPARATOR
Intervention: Control group physicians
Number of subjects: 88000
Study: 19201627

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative
Number of subjects: 90

Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 90
Study: 16639483

Group type: EXPERIMENTAL
Intervention: Bone sparing agents (hormone therapy, bisphosphonates, PTH 1‐34)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates (alendronate, risedronate)
Number of subjects: 0
Study: 15309591

Group type: EXPERIMENTAL
Intervention: 25 mg rofecoxib
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 11547741

Group type: EXPERIMENTAL
Intervention: Surgery plus postoperative chemoradiotherapy
Number of subjects: 556

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 556
Study: 9261583

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with cefazolin
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 280

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Clean-contaminated surgery
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Contaminated surgery
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Dirty surgery
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Patients with septic complications
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Patients without septic complications
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Patients without infection
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Patients with infection
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Sepsis-related death
Number of subjects: 280
Study: 8337215

Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion during panic attack
Number of subjects: 0
Study: 3013442

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (M) with VAC (vincristine, doxorubicin, and cyclophosphamide) at a lower dosage, given every 4 weeks for 8 courses.
Number of subjects: 309

Group type: COMPARATOR
Intervention: No maintenance chemotherapy (NM), no further treatment until relapse.
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Not applicable (for limited disease patients).
Number of subjects: 309
Study: 29556792

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (16 weeks)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 103
Study: 26376111

Group type: EXPERIMENTAL
Intervention: 100 mg PD‐0360324
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 150 mg PD‐0360324
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PD‐0360324 (both doses)
Number of subjects: 28
Study: 23983177

Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study: 21208766

Group type: EXPERIMENTAL
Intervention: Metronome-guided CPR at 80 ticks/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronome-guided CPR at 100 ticks/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronome-guided CPR at 120 ticks/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronome-guided CPR at 140 ticks/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronome guidance (general)
Number of subjects: 0
Study: 20455761

Group type: EXPERIMENTAL
Intervention: Nonnucleoside reverse transcriptase inhibitors (NNRTIs) - nevirapine (NVP) and efavirenz (EFV)
Number of subjects: 136
Study: 18670379

Group type: EXPERIMENTAL
Intervention: Eversion Carotid Endarterectomy (EEA)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Conventional Carotid Endarterectomy (CEA)
Number of subjects: 201
Study: 15749485

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50 mg on days 5-9
Number of subjects: 31

Group type: COMPARATOR
Intervention: Spontaneous menstrual cycles (Control)
Number of subjects: 31
Study: 12605581

Group type: EXPERIMENTAL
Intervention: Acute smoking
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 12
Study: 11025237

Group type: EXPERIMENTAL
Intervention: Subarachnoid injection of 12 mg hyperbaric bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anesthesia only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 9122535

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg
Number of subjects: 67
Study: 1900010

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 6666218

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg orally every 6 h for 3 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (initial dose of 40 mg orally)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chronic oral isosorbide dinitrate (40 mg every 6 h)
Number of subjects: 30
Study: 30472749

Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate (Cal/BD) aerosol foam (0.005%/0.05%) for 4 weeks
Number of subjects: 749
Study: 29542262

Group type: EXPERIMENTAL
Intervention: Intensive counseling, pharmacotherapy, text‐messaging, and financial incentives
Number of subjects: 29

Group type: COMPARATOR
Intervention: Enhanced usual care (brief counseling)
Number of subjects: 29
Study: 26718807

Group type: EXPERIMENTAL
Intervention: Knowledge-based and skills-based training programme for physicians
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 1124
Study: 24737912

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Golimumab (both dosages)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study: 22956863

Group type: EXPERIMENTAL
Intervention: 100 mg PBE supplementation once daily
Number of subjects: 112

Group type: COMPARATOR
Intervention: 40 mg PBE supplementation once daily
Number of subjects: 112
Study: 19262226

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8611

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 8611
Study: 17532750

Group type: EXPERIMENTAL
Intervention: TCL/MMF (n=180)
Number of subjects: 290

Group type: COMPARATOR
Intervention: CsA/MMF (n=110)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: MMF dose, MPA‐AUC, and the 2 h AUCs of MPAG and AcMPAG
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Plasma AcMPAG and MPAG concentrations
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: MPA‐AUC
Number of subjects: 290
Study: 15114202

Group type: EXPERIMENTAL
Intervention: Ampofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diprivan
Number of subjects: 60
Study: 11170129

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol
Number of subjects: 200

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 200
Study: 9775542

Group type: EXPERIMENTAL
Intervention: Auditory substitution using a personal computer connected to a miniature head-fixed video camera and headphones for real-time image processing and auditory signal generation.
Number of subjects: 0
Study: 8153225

Group type: EXPERIMENTAL
Intervention: Pregnancy counseling including abortion information
Number of subjects: 79

Group type: COMPARATOR
Intervention: Pregnancy counseling excluding abortion information
Number of subjects: 79

Group type: COMPARATOR
Intervention: Pregnancy counseling excluding abortion information with reminder of the 'gag rule'
Number of subjects: 79
Study: 3347071

Group type: EXPERIMENTAL
Intervention: 50 mg of diphenhydramine and 300 mg of cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0
Study: 30463394

Group type: EXPERIMENTAL
Intervention: Dietary intakes during pregnancy
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Dietary recommendations adherence
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Dietary variables
Number of subjects: 702
Study: 27618657

Group type: EXPERIMENTAL
Intervention: Pancreatic exocrine replacement therapy (PERT) consisting of 6-9 capsules of pancreatin (457.7 mg/capsule), taken two capsules three times daily during main meals and one capsule up to three times daily for snacks
Number of subjects: 67
Study: 24099824

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL) for calcium oxalate monohydrate (COM) calculi
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL) for mixed oxalate (COMix) calculi
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL) for carbonate apatite (CA) calculi
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL) for uric acid (UA) calculi
Number of subjects: 193
Study: 22486159

Group type: EXPERIMENTAL
Intervention: Crushed chlorthalidone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Crushed hydrochlorothiazide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Crushed lisinopril
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Crushed lercanidipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crushed atenolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crushed bisoprolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crushed enalapril
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crushed ramipril
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crushed amlodipine
Number of subjects: 20
Study: 20618098

Group type: EXPERIMENTAL
Intervention: Honey (HG)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DMG)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPHG)
Number of subjects: 139
Study: 18598124

Group type: EXPERIMENTAL
Intervention: Umbilical cord arterial blood pH levels (pHa) at delivery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Umbilical cord arterial blood pH levels (pHa) at delivery (subset with pHa <= 7.20)
Number of subjects: 0
Study: 15800160

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sham depletion
Number of subjects: 47
Study: 12419743

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/m(2)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Combination chemotherapy (FEC: fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), cyclophosphamide 500 mg/m(2))
Number of subjects: 260

Group type: COMPARATOR
Intervention: Combination chemotherapy (FEC)
Number of subjects: 260
Study: 10336110

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phen/fen (phentermine and fenfluramine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multivitamin
Number of subjects: 0
Study: 7582281

Group type: EXPERIMENTAL
Intervention: salbutamol, 200 micrograms four times per day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: budesonide, 400 micrograms four times per day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: salbutamol and budesonide combination
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study: 2116678

Group type: EXPERIMENTAL
Intervention: Indoor physical training programme
Number of subjects: 36
Study: 7247638

Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined EMG and theta feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sensorimotor rhythm (SMR) feedback
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 48
Study: 30887764

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Cyclic OCP
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: OCP
Number of subjects: 309
Study: 27998620

Group type: EXPERIMENTAL
Intervention: Tocilizumab, an interleukin‐6 receptor‐alpha inhibitor
Number of subjects: 251
Study: 25917295

Group type: EXPERIMENTAL
Intervention: Intensive Short-Term Dynamic (ISTDP) residential treatment program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (wait-list control)
Number of subjects: 60
Study: 23890779

Group type: EXPERIMENTAL
Intervention: Immunomagnetically purged PBSC
Number of subjects: 486

Group type: COMPARATOR
Intervention: Non-purged PBSC
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Purged PBSC
Number of subjects: 486
Study: 21891885

Group type: COMPARATOR
Intervention: Conventional heat‐polymerization technique
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RS tension system
Number of subjects: 20
Study: 19524334

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with agalsidase alpha or agalsidase beta
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 0
Study: 15994387

Group type: EXPERIMENTAL
Intervention: eformoterol 12 microg b.i.d.
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: fluticasone 250 microg b.i.d.
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: montelukast 10 mg q.d.
Number of subjects: 58
Study: 12568841

Group type: EXPERIMENTAL
Intervention: Immediate oral contraceptive start
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional oral contraceptive start
Number of subjects: 113
Study: 10235086

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Trapidil 300 mg/day
Number of subjects: 723

Group type: COMPARATOR
Intervention: No antiplatelets
Number of subjects: 723
Study: 8909381

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF 0.03 microgram/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF 0.1 microgram/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF 0.3 microgram/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF 1.0 microgram/kg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 1757831

Group type: EXPERIMENTAL
Intervention: Endotracheal suction with saline instillation (0.25-0.5 ml)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Endotracheal suction without saline instillation
Number of subjects: 27
Study: 6624697

Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol supplement of 800 IU
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: beta‐carotene supplement of 30 mg (5000 retinol equivalents)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: retinyl palmitate supplement of 25,000 IU (13,750 retinol equivalents)
Number of subjects: 59
Study: 31337365

Group type: EXPERIMENTAL
Intervention: Integrated network approach of preventive care for overweight children
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (overweight or obese children outside 's-Hertogenbosch)
Number of subjects: 180
Study: 27748014

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 81

Group type: COMPARATOR
Intervention: DBs
Number of subjects: 81
Study: 26031760

Group type: EXPERIMENTAL
Intervention: Lower UPSIT scores (impaired odor identification)
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: First quartile of UPSIT scores
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Second quartile of UPSIT scores
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Third quartile of UPSIT scores
Number of subjects: 1169

Group type: COMPARATOR
Intervention: Fourth quartile of UPSIT scores (highest scores)
Number of subjects: 1169
Study: 23747131

Group type: EXPERIMENTAL
Intervention: Concomitant therapy: omeprazole 20mg, amoxicillin 1g, clarithromycin 500 mg, and tinidazole 500 mg for 5 days
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Sequential therapy: omeprazole 20mg and amoxicillin 1g for 5 days followed by omeprazole 20mg, clarithromycin 500 mg, and tinidazole 500 mg for 5 days
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Hybrid therapy: omeprazole 20mg, and amoxicillin 1g for 7 days followed by omeprazole 20mg, amoxicillin 1g, clarithromycin 500 mg, and tinidazole 500 mg for 7 days
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Second-line therapy: omeprazole 20mg, levofloxacin 250 mg, and amoxicillin 1g, all given twice daily for 10 days
Number of subjects: 270
Study: 20665553

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open-label treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19722254

Group type: EXPERIMENTAL
Intervention: 3,4-Diaminopyridine (DAP) up to 75-80 mg/day
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7